Press release
Investigation announced for Investors in shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)

An investigation for investors in Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) shares over potential securities laws violations.
Investors who purchased shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Atea Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Boston, MA based Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections.
On October 19, 2021, Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) issued a press release “report[ing] that the global Phase 2 MOONSONG trial evaluating AT-527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms.” Accordingly, Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) stated that it was “assessing potential modifications to the global Phase 3 MORNINGSKY trial including the trial’s primary endpoint and patient population.” On this news, Atea’s stock price fell $26.80 per share, or 65.98%, to close at $13.82 per share on October 19, 2021. Then, on January 6, 2022, Morgan Stanley lowered its recommendation for Atea stock to Underweight from Equal-Weight, citing a lackluster market potential for AT-527 and opining that the product candidate “has missed the critical window to achieve a major bolus of COVID sales.”
Shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) declined from $46.91 per share on October 4, 2021, to as low as $7.37 per share on November 24, 2021.
Those who purchased shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) here
News-ID: 2538318 • Views: …
More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…

Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…

Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…

Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Atea
Segmentation Outlook - Global Respiratory Syncytial Virus Market | Atea Pharmace …
Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the respiratory syncytial virus market. This comprehensive report aims to equip businesses with invaluable insights and data, enabling them to make informed decisions and stay one step ahead of the competition.
The respiratory syncytial virus market is expected to reach revenue of US$ 4,202.6 million by 2027, growing at a CAGR of 14.9% over…
Software Resellers Market Sets the Table for Continued Growth: Dell Technologies …
The latest study released on the Global Software Resellers Market by AMA Research evaluates market size, trend, and forecast to 2027. The Software Resellers market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Download Sample Report…
Investigation announced for Investors in Atea Pharmaceuticals, Inc. (NASDAQ: AVI …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Atea Pharmaceuticals, Inc.
Investors who purchased shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Atea Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Boston, MA…
Software Resellers Market to See Thriving Worldwide | Atea, Dell Technologies, D …
Advance Market Analytics published a new research publication on "Software Resellers Market Insights, to 2026" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Software Resellers market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in…
Respiratory Syncytial Virus market Active Review by Key Members | AbbVie, Inc., …
Astute Analytica's analysis of the Respiratory Syncytial Virus Market is a comprehensive look at the current state of this business vertical and provides a brief description of its segmentation. In addition to an accurate prediction of the market scenario over the forecast period, the report also provides market size estimation based on sales volume and valuation. The study highlights the top companies comprising the competitive landscape of the Respiratory Syncytial…
Respiratory Syncytial Virus Market Installed For Attached Leg Of Research | AbbV …
Astute Analytica's analysis of the Respiratory Syncytial Virus Market is a comprehensive look at the current state of this business vertical and provides a brief description of its segmentation. In addition to an accurate prediction of the market scenario over the forecast period, the report also provides market size estimation based on sales volume and valuation. The study highlights the top companies comprising the competitive landscape of the Respiratory Syncytial…